Wave (WVE) Q2 Revenue Drops 56%

Wave Life Sciences is dedicated to developing RNA-based medicines using its proprietary PRISM platform. This technology enables the company to design stereopure oligonucleotides -- specialized, chemically controlled strands of nucleic acids -- allowing greater control over drug properties like efficacy and safety. By leveraging this approach, it aims to create therapies for a wide range of genetic disorders, from rare conditions to broader public health challenges. Recently, Wave Life Sciences has built a d ...